A rapid quantitative PCR-based assay for testing antiviral agents against human adenoviruses demonstrates type specific differences in ribavirin activity

Antiviral Research

Volumn 72, Issue 1, 2006, Pages 34-41

  Stock, Rüdiger ^a   Harste, Gabi ^a   Madisch, Ijad ^a   Heim, Albert ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adenovirus; Immunosuppression; Phenotypic assay; Quantitative PCR; Ribavirin

Indexed keywords

CIDOFOVIR; RIBAVIRIN; VIRUS DNA;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SCREENING; HUMAN; HUMAN ADENOVIRUS; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROTYPE; VIRUS INFECTION; VIRUS ISOLATION; VIRUS REPLICATION;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CYTOPATHOGENIC EFFECT, VIRAL; DNA PROBES; DNA, VIRAL; HUMANS; POLYMERASE CHAIN REACTION; RIBAVIRIN; SPECIES SPECIFICITY;

ADENOVIRIDAE; HUMAN ADENOVIRUS;

EID: 33746795182     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.03.009     Document Type: Article

References (42)

1. Arav-Boger R., Echavarria M., Forman M., Charache P., and Persaud D. Clearance of adenoviral hepatitis with ribavirin therapy in a pediatric liver transplant recipient. Pediatr. Infect. Dis. J. 19 (2000) 1097-1100
2. Baldwin A., Kingman H., Darville M., Foot A.B., Grier D., Cornish J.M., Goulden N., Oakhill A., Pamphilon D.H., Steward C.G., and Marks D.I. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant. 26 (2000) 1333-1338
3. Blasi F. Ribavirin. It. J. Chest Dis. 57 (2003) 31-42
4. Bordigoni P., Carret A.S., Venard V., Witz F., and Le Faou A. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin. Infect. Dis. 32 (2001) 1290-1297
5. Carrigan D.R. Adenovirus infections in immunocompromised patients. Am. J. Med. 102 (1997) 71-74
6. Chakrabarti S., Mautner V., Osman H., Collingham K.E., Fegan C.D., Klapper P.E., Moss P.A., and Milligan D.W. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 100 (2002) 1619-1627
7. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984) 27-55
8. Claas E.C., Schilham M.W., de Brouwer C.S., Hubacek P., Echavarria M., Lankester A.C., van Tol M.J., and Kroes A.C. Internally controlled real-time PCR monitoring of adenovirus DNA load in serum or plasma of transplant recipients. J. Clin. Microbiol. 43 (2005) 1738-1744
9. Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y., Hong Z., Andino R., and Cameron C.E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6 (2000) 1375-1379
10. Emovon O.E., Lin A., Howell D.N., Afzal F., Baillie M., Rogers J., Baliga P.K., Chavin K., Nickeleit V., Rajagapalan P.R., and Self S. Refractory adenovirus infection after simultaneous kidney-pancreas transplantation: successful treatment with intravenous ribavirin and pooled human intravenous immunoglobulin. Nephrol. Dial. Transplant. 18 (2003) 2436-2438
11. Gavin P.J., and Katz B.Z. Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. Pediatrics 110 (2002) e9
12. Gordon Y.J., Romanowski E., Araullo-Cruz T., Seaberg L., Erzurum S., Tolman R., and De Clercq E. Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2′-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro. Antiviral Res. 16 (1991) 11-16
13. Goswami B.B., Borek E., Sharma O.K., Fujitaki J., and Smith R.A. The broad-spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 89 (1979) 830-836
14. Heim A., Ebnet C., Harste G., and Pring-Akerblom P. Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J. Med. Virol. 70 (2003) 228-239
15. Heim A., Grumbach I., Pring-Akerblom P., Stille-Siegener M., Muller G., Kandolf R., and Figulla H.R. Inhibition of coxsackievirus B3 carrier state infection of cultured human myocardial fibroblasts by ribavirin and human natural interferon-alpha. Antiviral Res. 34 (1997) 101-111
16. Hierholzer J.C., and Killington R.A. Virus isolation and quantitation. In: Mahy B.W.J., and Kangro H.O. (Eds). Virology Methods Manual (1996), Academic Press, London 25-46
17. Kirsi J.J., McKernan P.A., Burns III N.J., North J.A., Murray B.K., and Robins R.K. Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin. Antimicrob. Agents Chemother. 26 (1984) 466-475
18. Kojaoghlanian T., Flomenberg P., and Horwitz M.S. The impact of adenovirus infection on the immunocompromised host. Rev. Med. Virol. 13 (2003) 155-171
19. La Rosa A.M., Champlin R.E., Mirza N., Gajewski J., Giralt S., Rolston K.V., Raad I., Jacobson K., Kontoyiannis D., Elting L., and Whimbey E. Adenovirus infections in adult recipients of blood and marrow transplants. Clin. Infect. Dis. 32 (2001) 871-876
20. Lankester A.C., Heemskerk B., Claas E.C., Schilham M.W., Beersma M.F., Bredius R.G., van Tol M.J., and Kroes A.C. Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection. Clin. Infect. Dis. 38 (2004) 1521-1525
21. Laskin O.L., Longstreth J.A., Hart C.C., Scavuzzo D., Kalman C.M., Connor J.D., and Roberts R.B. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin. Pharmacol. Ther. 41 (1987) 546-555
22. Lertora J.J., Rege A.B., Lacour J.T., Ferencz N., George W.J., VanDyke R.B., Agrawal K.C., and Hyslop Jr. N.E. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. 50 (1991) 442-449
23. Lion T., Baumgartinger R., Watzinger F., Matthes-Martin S., Suda M., Preuner S., Futterknecht B., Lawitschka A., Peters C., Potschger U., and Gadner H. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 102 (2003) 1114-1120
24. Ljungman P. Treatment of adenovirus infections in the immunocompromised host. Eur. J. Clin. Microbiol. Infect. Dis. 23 (2004) 583-588
25. Mentel R., Kinder M., Wegner U., von Janta-Lipinski M., and Matthes E. Inhibitory activity of 3′-fluoro-2′-deoxythymidine and related nucleoside analogues against adenoviruses in vitro. Antiviral Res. 34 (1997) 113-119
26. Mentel R., Matthes E., von Janta-Lipinski M., and Wegner U. Fluorescent focus reduction assay for the screening of antiadenoviral agents. J. Virol. Meth. 59 (1996) 99-104
27. Miyamura K., Hamaguchi M., Taji H., Kanie T., Kohno A., Tanimoto M., Saito H., Kojima S., Matsuyama T., Kitaori K., Nagafuji K., Sato T., and Kodera Y. Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors. Bone Marrow Transplant. 25 (2000) 545-548
28. Morfin F., Dupuis-Girod S., Mundweiler S., Falcon D., Carrington D., Sedlacek P., Bierings M., Cetkovsky P., Kroes A.C., van Tol M.J., and Thouvenot D. In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antiviral Ther. 10 (2005) 225-229
29. Naesens L., Lenaerts L., Andrei G., Snoeck R., Van Beers D., Holy A., Balzarini J., and De Clercq E. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob. Agents Chemother. 49 (2005) 1010-1016
30. Page T., and Connor J.D. The metabolism of ribavirin in erythrocytes and nucleated cells. Int. J. Biochem. 22 (1990) 379-383
31. Scheidel L.M., and Stollar V. Mutations that confer resistance to mycophenolic acid and ribavirin on Sindbis virus map to the nonstructural protein nsP1. Virology 181 (1991) 490-499
32. Schleuning M., Buxbaum-Conradi H., Jager G., and Kolb H.J. Intravenous ribavirin for eradication of respiratory syncytial virus (RSV) and adenovirus isolates from the respiratory and/or gastrointestinal tract in recipients of allogeneic hematopoietic stem cell transplants. Hematol. J. 5 (2004) 135-144
33. Schnurr D., and Dondero M.E. Two new candidate adenovirus serotypes. Intervirology 36 (1993) 79-83
34. Seidemann K., Heim A., Pfister E.D., Köditz H., Beilken A., Sander A., Melter M., Sykora K.W., Sasse M., and Wessel A. Monitoring of adenovirus infection in pediatric transplant recipients by quantitative PCR: report of six cases and review of the literature. Am. J. Transplant. 4 (2004) 2102-2108
35. Sidwell R.W., Huffman J.H., Khare G.P., Allen L.B., Witkowski J.T., and Robins R.K. Broad-spectrum antiviral activity of Virazole: 1-β-d-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177 (1972) 705-706
36. Streeter D.G., Witkowski J.T., Khare G.P., Sidwell R.W., Bauer R.J., Robins R.K., and Simon L.N. Mechanism of action of 1-β-d-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. U.S.A. 70 (1973) 1174-1178
37. Swenson P.D., Wadell G., Allart A., Hierholzer J.C., Murray P.R., Baron E.J., Pfaller M., Jorgensen J., and Yolken R. Adenoviruses. In: Murray P.R., et al. (Ed). Clinical Microbiology (2003), American Society for Microbiology, Washington, DC 1404-1417
38. Temperley S.M., and Hay R.T. Recognition of the adenovirus type 2 origin of DNA replication by the virally encoded DNA polymerase and preterminal proteins. EMBO J. 11 (1992) 761-768
39. Venard V., Carret A., Corsaro D., Bordigoni P., and Le Faou A. Genotyping of adenoviruses isolated in an outbreak in a bone marrow transplant unit shows that diverse strains are involved. J. Hosp. Infect. 44 (2000) 71-74
40. Vignuzzi M., Stone J.K., and Andino R. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res. 107 (2005) 173-181
41. Wutzler P., Sauerbrei A., Klocking R., Brogmann B., and Reimer K. Virucidal activity and cytotoxicity of the liposomal formulation of povidone-iodine. Antiviral Res. 54 (2002) 89-97
42. Zhang Y., Jamaluddin M., Wang S., Tian B., Garofalo R.P., Casola A., and Brasier A.R. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J. Virol. 77 (2003) 5933-5947